Colchicine to prevent cardiovascular events in thoracic surgery patients with or without coronary artery disease: a secondary analysis.

Open HeartSep 15, 2026 (epub)
Clinical ResearchCardiologyGeneral Surgery

Ghazal Razeghi, Michael K Wang, P J Devereaux et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of the COP-AF randomized controlled trial examined the impact of coronary artery disease (CAD) on postoperative ischemic outcomes in thoracic surgery patients. Among 3209 patients, those with CAD had a higher incidence of myocardial injury after non-cardiac surgery (29.3% vs 18.2%, adjusted HR 1.53). Colchicine did not show differential effects based on CAD status.

Key findings

  • Patients with CAD had a 29.3% incidence of myocardial injury after surgery compared to 18.2% in non-CAD patients.
  • The adjusted hazard ratio for myocardial injury in CAD patients was 1.53 (95% CI 1.22 to 1.92; p<0.001).
  • Colchicine showed a hazard ratio of 0.82 for MINS in CAD patients and 0.91 in non-CAD patients.
  • Death, stroke, or MINS occurred in 30.2% of CAD patients versus 18.6% of non-CAD patients.

Why it matters

Understanding the differential risks of myocardial injury and other ischemic outcomes in patients with CAD undergoing thoracic surgery is crucial for optimizing perioperative care and risk management strategies.

Source

PubMed · PMID 42744416

Published in Open Heart. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.